Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2009891PMC
http://dx.doi.org/10.1038/bjc.1979.109DOI Listing

Publication Analysis

Top Keywords

receptor-bearing phagocytic
4
phagocytic cells
4
cells syngeneic
4
syngeneic tumours
4
tumours parvum-
4
parvum- carrageenan-treated
4
carrageenan-treated mice
4
receptor-bearing
1
cells
1
syngeneic
1

Similar Publications

Article Synopsis
  • Anti-GD2 antibody therapy offers benefits for neuroblastoma patients, but its effectiveness is limited by the tumor's immunosuppressive environment.
  • Research shows that using copper chelation can enhance this therapy by improving immune responses, specifically by boosting the activity of neutrophils that help fight the tumor.
  • The study suggests repurposing the approved copper chelator Cuprior as a safe and effective method to improve the outcomes of anti-GD2 therapy in neuroblastoma patients.
View Article and Find Full Text PDF

Multiple Sclerosis: Microglia, Monocytes, and Macrophage-Mediated Demyelination.

J Neuropathol Exp Neurol

October 2021

Department of Neurology, Royal North Shore Hospital, St. Leonards, NSW, Australia.

This study examined the roles of microglia and monocytes in myelin destruction in patients with early multiple sclerosis (MS). Twenty-two cases were studied; the clinical duration was <9 weeks in 10 cases. Twenty myeloid cell subtypes or categories were identified including 2 cell types not known previously to occur in demyelinating diseases.

View Article and Find Full Text PDF

Vaccines are essential to control the spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and to protect the vulnerable population. However, one safety concern of vaccination is the possible development of antibody-dependent enhancement (ADE) of SARS-CoV-2 infection. The potential infection of Fc receptor bearing cells such as macrophages, would support continued virus replication and inflammatory responses, and thereby potentially worsen the clinical outcome of COVID-19.

View Article and Find Full Text PDF

Identification and functional characterization of a Siglec-7 counter-receptor on K562 cells.

J Biol Chem

August 2021

Bioscience and Biotechnology Center, Nagoya University, Chikusa, Nagoya, Japan; Graduate School of Bioagricultural Sciences, Nagoya University, Chikusa, Nagoya, Japan; Integrated Glyco-Biomedical Research Center (iGMed), Nagoya University, Chikusa, Nagoya, Japan; Institute for Glyco-Core Research (iGCORE), Nagoya University, Chikusa, Nagoya, Japan. Electronic address:

Sialic acid (Sia)-binding immunoglobulin-like lectin 7 (Siglec-7) is an inhibitory receptor primarily expressed on natural killer (NK) cells and monocytes. Siglec-7 is known to negatively regulate the innate immune system through Sia binding to distinguish self and nonself; however, a counter-receptor bearing its natural ligand remains largely unclear. Here, we identified a counter-receptor of Siglec-7 using K562 hematopoietic carcinoma cells presenting cell surface ligands for Siglec-7.

View Article and Find Full Text PDF

Bladder urothelial carcinoma (BUC) is a chronic relapsing urological malignancy, which poses a serious threat to human life. Non-resolving chronic-inflammation at the neoplastic site is associated consistently with inducing tumor-progression and poor patient outcomes. Interleukin 23 receptor (IL-23R) is a key element in T-helper 17 cell-mediated inflammatory process, that plays a critical role in orchestrating tumor-promoting inflammation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!